

1 **ORP1L regulates dynein clustering on endolysosomal membranes in response to**
2 **cholesterol levels**

3 Shreyasi Thakur¹, Peter K. Relich¹, Elena M. Sorokina¹, Melina T. Gyparaki², Melike
4 Lakadamyali^{1,3,*}

5 ¹ Department of Physiology, Perelman School of Medicine, University of Pennsylvania

6 ² Department of Biology, School of Arts and Sciences, University of Pennsylvania

7 ³ Department of Cell and Developmental Biology, Perelman School of Medicine, University of
8 Pennsylvania

9 * Correspondence should be sent to: melikel@penmedicine.upenn.edu

10 **Abstract**

11 The sub-cellular positioning of endolysosomes is crucial for regulating their function. Particularly,
12 the positioning of endolysosomes between the cell periphery versus the peri-nuclear region
13 impacts autophagy, mTOR (mechanistic target of rapamycin) signaling and other processes. The
14 mechanisms that regulate the positioning of endolysosomes at these two locations are still being
15 uncovered. Here, using super-resolution microscopy, we show that the retrograde motor dynein
16 forms nano-clusters on endolysosomal membranes containing 1-2 dyneins, with an average of
17 ~3 nanoclusters per endolysosome. These data suggest that a very small number of dynein
18 motors (1-6) drive endolysosome motility. Surprisingly, dynein nano-clusters are slightly larger on
19 peripheral endolysosomes having higher cholesterol levels compared to peri-nuclear ones. By
20 perturbing endolysosomal membrane cholesterol levels, we show that dynein copy number within
21 nano-clusters is influenced by the amount of endolysosomal cholesterol while the total number of
22 nano-clusters per endolysosome is independent of cholesterol. Finally, we show that the dynein
23 adapter protein ORP1L (Oxysterol Binding Protein Homologue) regulates the number of dynein
24 motors within nano-clusters in response to cholesterol levels. We propose a new model by which
25 endolysosomal transport and positioning is influenced by the cholesterol sensing adapter protein
26 ORP1L, which influences dynein's copy number within nano-clusters.

27 Introduction

28 Late endosomes, lysosomes and autolysosomes constitute a broad class of sub-cellular
29 compartments (Klumperman and Raposo, 2014; Wijdeven et al., 2016) that we will refer to here
30 as endolysosomes for simplicity. Endolysosomal compartments play key cellular roles including
31 transport of cellular proteins destined for degradation, metabolic sensing, membrane repair and
32 signaling (Gould and Lippincott-Schwartz, 2009). The maturation level, fusion capacity with other
33 sub-cellular compartments and downstream function of endolysosomes are regulated by their
34 intracellular transport and sub-cellular positioning. For example, dispersal of lysosomes from the
35 peri-nuclear region to the cell periphery increases their association with mTORC1 (mechanistic
36 target of rapamycin complex 1) and leads to downregulation of autophagy (Kimura et al., 2008;
37 Korolchuk and Rubinsztein, 2011; Korolchuk et al., 2011; Pu et al., 2016). In addition, it is known
38 that endolysosomes have heterogeneity in their membrane lipid composition, which influences their
39 function. In general, different cellular organelles have unique lipid composition and there is a lipid
40 gradient from ER to the plasma membrane with highest amount of cholesterol and sphingolipids
41 present in the plasma membrane (Abdul-Hammed et al., 2010; Brugger et al., 2000). Spatially
42 compartmentalized endolysosomal populations also have distinct membrane lipid composition,
43 resulting in varying membrane proteomics and lipid-protein interplay, effecting their maturation
44 and functions. For example, early endosomes mostly located peripherally have higher membrane
45 phosphatidylinositol 3-phosphate (PI(3)P) and cholesterol content (Arumugam and Kaur, 2017;
46 Bissig and Gruenberg, 2013; Huotari and Helenius, 2011) and are rich in PI(3)P-binding proteins
47 which regulates lysosome targeting and retrograde transport (Bissig and Gruenberg, 2013;
48 Lemmon, 2008). More peri-nuclearly enriched late endosomes, on the other hand, have limiting
49 membranes with low phosphatidylserine, cholesterol, and sphingomyelin content, resulting in
50 distinct membrane dynamics, proteomics and functions (Kobayashi et al., 2002; Redpath et al.,
51 2020).

52 The transport and subcellular positioning of endolysosomes are in turn regulated by a myriad of
53 mechanisms (Maday et al., 2014) including motor activation (Elshenawy et al., 2020; Fu and
54 Holzbaur, 2014; Fu et al., 2014), motor tug-of-war (Belyy et al., 2016; Hendricks et al., 2010;
55 Soppina et al., 2009) and association of motors with microtubule tracks having distinct post-
56 translational modifications (Guardia et al., 2016; Mohan et al., 2019; Nirschl et al., 2016).
57 Peripheral transport of endolysosomes is mediated by kinesin motors belonging to different
58 kinesin families (Kif5, Kif1, Kif3) (Brown et al., 2005; Cardoso et al., 2009; Encalada et al., 2011;
59 Mohan et al., 2019; Rosa-Ferreira and Munro, 2011), whereas dynein is responsible for their

60 retrograde transport toward the perinuclear region (Granger et al., 2014; Reck-Peterson et al.,
61 2018). Recent discovery of dynein activating adapters have revolutionized our understanding of
62 how dynein mediates efficient retrograde transport (Elshenawy et al., 2020; McKenney et al.,
63 2014; Olenick and Holzbaur, 2019; Reck-Peterson et al., 2018; Schroeder and Vale, 2016).
64 Dynein assembles into an autoinhibitory, weakly processive conformation, while dynein activating
65 adaptors are crucial for dynein's assembly with dynactin and the processive motility of the dynein-
66 dynactin complex on microtubules (Chowdhury et al., 2015; McKenney et al., 2014; Schroeder
67 and Vale, 2016; Urnavicius et al., 2018). Recent Cryo-EM studies showed that certain early
68 endosomal dynein activating adapters including BICD2 and Hook3 recruit two dynein dimers
69 (Urnavicius et al., 2018). *In vitro* assays further showed that these heteromeric dynein complexes
70 move faster and navigate obstacles better compared to single dynein (Elshenawy et al., 2019;
71 Ferro et al., 2019; Urnavicius et al., 2018). Hence, in addition to mediating dynein's interaction
72 with dynactin and bringing dynein out of its auto-inhibitory confirmation, these activators further
73 improve the efficiency of dynein mediated motility by allowing two copies of dynein to assemble
74 together into complexes. Yet, to date, the stoichiometry of adapter-dynein-dynactin complexes on
75 sub-cellular compartments *in vivo* and how these complexes are spatially organized on the
76 membrane of sub-cellular compartments are not known. Dynein is recruited to endolysosomal
77 compartments via the cholesterol-sensing tripartite complex Rab7-RILP-ORP1L (Johansson et
78 al., 2007; Pfeffer, 2001; Rocha et al., 2009). Whether this tripartite complex can recruit multiple
79 copies of dynein dimers to improve the efficiency of retrograde transport of endolysosomal
80 compartments in response to cellular cues is unknown.

81 Super-resolution is a powerful tool for studying spatial nano-organization of proteins within the
82 cell, yet, only a handful of studies have been carried out to date to visualize proteins on the
83 membrane of sub-cellular compartments (Franke et al., 2019; Puchner et al., 2013). Previously,
84 using super-resolution microscopy, we showed that dynein forms nano-clusters on microtubules
85 consisting of small teams of dynein motors (Cella Zanicchi et al., 2019; Zanicchi et al., 2017).
86 However, whether these nano-clusters are formed on the membrane of endolysosomes, the
87 mechanisms of nano-cluster formation and whether formation of larger nano-clusters containing
88 more dynein motors lead to more efficient retrograde transport are not known. Here, using
89 quantitative super-resolution microscopy, we show that dynein resides in on average ~3 nano-
90 clusters on endolysosomes, consisting of 1-2 dyneins, suggesting that on average a very small
91 total number of dynein motors (1-6) drive endolysosomal transport. Our data further suggest that
92 an increase in the percentage of dynein multimers present within the nano-clusters on
93 endolysosomes correlates with longer run lengths and faster velocity in the retrograde direction

94 as well as an increased peri-nuclear clustering of endolysosomes. The copy number of dynein
95 within nano-clusters is in turn regulated by membrane cholesterol levels and ORP1-L's cholesterol
96 sensing domain.

97

98 **Results**

99 **Dynein forms nano-clusters on endolysosomes containing 1-2 dynein motors with a switch** 100 **to larger nano-clusters on peripheral versus peri-nuclear endolysosomes.**

101 To visualize the spatial organization of dynein on endolysosomal membranes we expressed
102 ORP1L WT-mCherry in HeLa cells in which endogenous ORP1L was targeted by CRISPR/Cas9
103 mutagenesis (ORP1L-KO) (Zhao and Ridgway, 2017). The ORP1L- mCherry signal substantially
104 overlapped with that of CD63, an endolysosomal marker (Beatty, 2006; van der Kant et al., 2013;
105 Vanlandingham and Ceresa, 2009), indicating that ORP1L marks endolysosomes (Figure S1A).
106 Hence, we took ORP1L WT-mCherry positive sub-compartments in the wide-field images that
107 were isolated, round and diffraction limited in size (200-500 nm FWHM) as an endolysosome for
108 further analysis (Figure 1A and Figure S1B). To determine whether dynein was clustered on these
109 endolysosomes, we carried out super-resolution imaging of dynein labeled with an antibody
110 against the dynein intermediate chain (IC74). We validated the IC74 antibody using a HeLa cell
111 line stably expressing IC74 tagged with GFP (Kobayashi et al., 2002) (Figure S1C). There was
112 high co-localization between the GFP signal and the IC74 antibody (Manders coefficient 0.8 for
113 IC74 antibody colocalizing with GFP) showing that the IC74 antibody had high labeling specificity
114 and efficiency. Super-resolution images of IC74 revealed nano-clusters within the cell cytoplasm
115 similar to what we have previously demonstrated (Cella Zancchi et al., 2019) (Figure 1A-B). We
116 manually cropped the central intensity peak of ORP1L WT-mCherry positive endolysosomes
117 (Figure S1B and Methods) and used it as a mask in the super-resolution image to specifically
118 segment dynein nano-clusters that overlapped with an endolysosomal compartment (Figure 1A-
119 B). Dynein super-resolution images were further segmented into individual nano-clusters using a
120 previously developed Voronoi tessellation approach (Figure S1D) (Levet et al., 2015). We then
121 quantified the number of dynein nano-clusters as well as the number of localizations per dynein
122 nano-cluster for peripherally- and peri-nuclearly-positioned endolysosomes (Figure S1E and
123 Figure 1C). The peripheral and peri-nuclear endolysosomes were separated manually based on
124 their proximity to the cell nucleus (Figure S1F). Endolysosomes contained on average ~2 dynein
125 nano-clusters and there was no difference in the number of dynein nano-clusters associated to

126 peripheral or perinuclear endolysosomes (Figure S1E). The number of localizations per nano-
127 cluster is proportional to the nano-cluster size as well as to the copy number of dynein within
128 nano-clusters (Cella Zanicchi et al., 2019; Zanicchi et al., 2017). Surprisingly, we found that the
129 dynein nano-clusters associated to peripheral endolysosomes contained a significantly higher
130 number of localizations compared to peri-nuclear endolysosomes (Figure 1C, mean = 67 ± 1.9 for
131 peripheral and 54 ± 1.8 for perinuclear endolysosomes).

132 To obtain a quantitative estimate of the copy number of dynein within nano-clusters, we carried
133 out a calibration experiment in which we diluted the primary antibody by 100-fold, aiming to
134 sparsely label single copies of the dynein IC74 subunit (Ehmann et al., 2014) (Figure S1G and
135 Methods). We then used the number of localizations per nano-cluster in these sparse labeling
136 experiments as a calibration corresponding to single IC74 subunit (Figure 1C, Figure S1H). We
137 previously showed that fitting the distribution of number of localizations per nano-cluster to a linear
138 convolution of monomeric calibration functions ($f_1, f_2, f_3 \dots$) enables estimation of the copy number
139 composition of a protein of interest in super-resolution images (Zanicchi et al., 2017). We used
140 this approach and stopped the fitting when the residuals for the fit stopped changing, which
141 corresponded to f_3 for both peripheral and perinuclear endolysosomes (see Figure S1H for
142 residuals when fitting to $N=1$, $N=2$, $N=3$ and $N=4$). Using this approach, we estimated that nano-
143 clusters on peri-nuclear endolysosomes consist of 76% single IC74, 4% 2 IC74s, 20% 3 IC74s
144 and those on peripheral endolysosomes consist of 69% single IC74, 0.1% 2 IC74s, 31% 3 IC74s
145 (Figure S1H). Given that each dynein motor is a dimer of IC74, the presence of single IC74
146 subunits in the quantification is likely due to steric effects associated with labeling two subunits of
147 the same protein in close proximity. We thus took the monomeric IC74 weights in the fit to
148 represent a partially labeled single dynein motor. Further, the weights corresponding to trimeric
149 IC74 represent partially labelled dynein multimers, most likely consisting of 2 copies of dynein. It
150 is possible that the dimeric IC74 weight in the fit corresponds partially to a single dynein and
151 partially to dynein multimers. Since we could not clearly assign this population to a given category
152 (single versus multiple dynein) and since this population was a minority (0.1% and 4% on
153 peripheral and perinuclear endolysosomes, respectively) and would not affect our conclusions,
154 we excluded it from consideration. These data suggest that majority of dynein is present in single
155 copy within the nano-clusters and a small proportion of nanoclusters contain dynein multimers,
156 likely consisting of two copies of dynein. Interestingly, compared to peri-nuclear endolysosomes,
157 on peripheral endolysosomes the proportion of nano-clusters containing dynein multimers
158 increased by about 1.6-fold (from 20% to 31%) (Figure S1H). These differences in the dynein
159 clustering were not due to differences in the imaging depth of peripheral versus peri-nuclear

160 endolysosomes since cytosolic clusters not associated to endolysosomes analyzed from the
161 same peripheral and peri-nuclear regions showed no differences in the number of localizations
162 per nano-cluster (Figure S1I). It is important to mention that the proportion of multimeric dynein is
163 likely underestimated in these quantifications due to the steric hindrance problems in labeling
164 multiple copies of IC74 in close proximity and this problem will be exacerbated under conditions
165 in which endolysosomes contain a higher proportion of dynein multimers. Hence, the difference
166 in the proportion of dynein multimers between peripheral and perinuclear endolysosomes is likely
167 larger than our quantitative estimate. Overall, given that each endolysosome contains on average
168 ~3 dynein nano-clusters independent of its position within the cell, and the nano-clusters are
169 mainly composed of 1-2 dynein motors, these data suggest that a small total number of dynein
170 motors (1-6) drive the motility of endolysosomes. These results are consistent with previous
171 estimates using single step photobleaching and western blot analysis on lysosomal compartments
172 (Hendricks et al., 2010).

173 It is known that positioning of endolysosomal compartments in the cell affects their membrane
174 composition, maturation and signaling (Cabukusta and Neefjes, 2018; Hu et al., 2015; Hyttinen
175 et al., 2013). We thus asked if the membrane cholesterol content may be responsible for the
176 increase in the presence of 2 copies of dynein within the nano-clusters on peripheral
177 endolysosomes. To start addressing this question, we measured the cholesterol levels of
178 peripheral and peri-nuclear endolysosomes by labeling ORP1L WT-mCherry expressing HeLa
179 cells with filipin, a toxin that binds cholesterol. We measured the filipin intensity on ORP1L WT-
180 mCherry positive endolysosomes and found that membrane cholesterol levels of peripheral
181 endolysosomes (mean intensity = 454 ± 40 a.u.) were indeed higher compared to peri-nuclear
182 endolysosomes (mean intensity = 312 ± 19 a.u.) (Figure 1D). These results indicate a correlation
183 between endolysosomal membrane cholesterol levels, endolysosomal positioning and dynein
184 clustering.

185

186 **Membrane cholesterol levels influence dynein copy number within nano-clusters on** 187 **endolysosomes.**

188 To better understand the mechanisms behind dynein clustering and to causally relate dynein
189 clustering to endolysosomal membrane cholesterol levels, we manipulated cholesterol levels with
190 two commonly used drugs: U18666A that increases endolysosomal membrane cholesterol and
191 Lovastatin that decreases cellular and endolysosomal membrane cholesterol levels (Keyomarsi,

192 1996; Rocha et al., 2009). ORP1L WT-mCherry-positive endolysosomes in ORP1L KO HeLa cells
193 treated with U18666A indeed had higher membrane cholesterol levels (mean intensity =
194 3020 ± 183.5 a.u.) (by 4.5-fold) compared to those in cells treated with lovastatin (mean intensity =
195 668.2 ± 47.5 a.u.) as measured by filipin intensity (Figure S2A). We will refer to the endolysosomal
196 membrane cholesterol content of the U18666A and Lovastatin treated cells as ‘high cholesterol’
197 and ‘low cholesterol’ condition, respectively.

198 Super-resolution imaging revealed that for those endolysosomes that contained dynein nano-
199 clusters associated to them, the number of dynein nano-clusters per endolysosome was
200 independent of cholesterol levels (Figure S2B) but dynein nano-clusters on endolysosomal
201 compartments contained a significantly higher number of localizations under high cholesterol
202 compared to low cholesterol conditions (Figure 2A-B, mean = 71 ± 1.9 for high and 50 ± 1.9 for low
203 cholesterol).

204 These differences were not due to an increase in dynein expression level upon high cholesterol
205 drug treatment, as western blot analysis showed that the level of dynein expression did not
206 increase under high cholesterol treatment (Figure S2C). We once again fit the number of
207 localizations per nano-cluster distribution to the calibration data to determine dynein copy number
208 within nano-clusters under high and low cholesterol conditions, stopping the fit when the residuals
209 stopped changing substantially, which corresponded once again to f_3 (Figure S2D). Once again,
210 we assigned the weight for N=1 IC74 to single dynein (61% and 77% on high and low cholesterol
211 endolysosomes, respectively) and N=3 to multiple (likely 2) copies of dynein (38% and 18% on
212 high and low cholesterol endolysosomes, respectively). The proportion of nano-clusters
213 corresponding to a weight of N=2 IC74s was once again negligible (0.7% and 4% on high and
214 low cholesterol endolysosomes, respectively). This analysis showed that under high cholesterol
215 the proportion of nano-clusters containing two dyneins increased by ~2-fold (from 18% to 38%)
216 (Figure S2D). Finally, low cholesterol levels also led to an increase in the percentage of
217 endolysosomes that completely lacked dynein (Figure S2E, Low chol: 55%, High Chol: 27%).

218 We next analyzed the cholesterol levels and dynein nano-cluster size on peripheral and peri-
219 nuclear endolysosomes under the two cholesterol treatment conditions. In contrast to
220 physiological conditions, peripheral and peri-nuclear endolysosomes had similar cholesterol
221 levels (Figure S2F, High Cholesterol: mean intensity = 2998 ± 209 a.u. and 3152 ± 180 a.u. for
222 peripheral and peri-nuclear respectively and Low Cholesterol: mean intensity = 491 ± 55 a.u. and
223 480 ± 43 a.u. for peripheral and peri-nuclear, respectively) as measured by filipin intensity and
224 similar dynein clustering under both high and low cholesterol conditions (Figure 2C, High

225 cholesterol: mean localizations per cluster = 79 ± 9 and 70 ± 2 for peripheral and peri-nuclear
226 endolysosomes, respectively and Low Cholesterol: mean localizations per cluster = 50 ± 2.7 and
227 51 ± 2.8 for peripheral and peri-nuclear endolysosomes, respectively). Interestingly, the dynein
228 clustering level of peri-nuclear endolysosomes under physiological conditions (mean localizations
229 per cluster = 54 ± 1.8) was similar to those under low cholesterol conditions (mean localizations
230 per cluster = 51 ± 1.8) and the dynein clustering level of peripheral endolysosomes under
231 physiological conditions (mean localizations per cluster = 67 ± 1.9) was similar to those under high
232 cholesterol conditions (mean localizations per cluster = 79 ± 5) (Figure 2D). These results indicate
233 that cholesterol levels and not endolysosome positioning determine the level of dynein clustering
234 on endolysosomal membranes.

235 To determine whether these differences in dynein clustering correlated with changes in
236 endolysosomal transport, we determined the positioning and transport properties of
237 endolysosomes under high and low cholesterol conditions. It has previously been shown that high
238 cholesterol leads to peri-nuclear clustering of endolysosomes whereas low cholesterol leads to
239 their peripheral scattering (Rocha et al., 2009). Here we further confirmed that the positioning of
240 endolysosomes was indeed impacted by cholesterol levels, with low cholesterol leading to more
241 scattered and high cholesterol leading to more peri-nuclearly clustered endolysosomes (Figure
242 S2G), consistent with previous results. In addition, we measured the retrograde and anterograde
243 run length and the velocity of endolysosomes in live cell movies under low and high cholesterol
244 conditions (Figure 2E and F). While high cholesterol led to increased run length and velocity as
245 compared to low cholesterol in the retrograde direction (Figure 2E, mean run length = 2.7 ± 2 μm
246 and 1.9 ± 1 μm for high and low cholesterol and mean velocity = 1.7 ± 1 $\mu\text{m}/\text{sec}$ and 1 ± 1 $\mu\text{m}/\text{sec}$ for
247 high and low cholesterol, respectively), the anterograde run length was only slightly affected
248 (slightly longer run length in low cholesterol as compared to high cholesterol) and the anterograde
249 velocity was unchanged by cholesterol treatment (Figure 2F, mean run length = 1.2 ± 0.8 μm and
250 1.4 ± 0.9 μm for high and low cholesterol and mean velocity = 0.9 ± 0.4 $\mu\text{m}/\text{sec}$ and 1 ± 0.6 $\mu\text{m}/\text{sec}$
251 for high and low cholesterol, respectively). These results further suggest that increased dynein
252 clustering under high cholesterol likely leads to more efficient retrograde transport whereas
253 kinesin dependent anterograde transport is not affected.

254 Taken together our results show that membrane cholesterol levels impact not only dynein
255 recruitment but importantly also the level of dynein clustering and the proportion of dynein
256 multimers within nanoclusters on endolysosomal membranes.

257

258 **The cholesterol sensing domain of ORP1L regulates ORP1L clustering on endolysosomal**
259 **membranes in a cholesterol dependent manner.**

260 Dynein does not directly bind to endolysosomal membranes and the mechanisms that can lead
261 to the formation of nano-clusters with increased dynein copy number are unknown. Dynein is
262 recruited to endolysosomes through a tripartite complex of Rab7-ORP1L-RILP (Johansson et al.,
263 2007; Pfeffer, 2001; Rocha et al., 2009). ORP1L contains multiple lipid binding domains that allow
264 it to bind to either oxysterols or phospholipids (Johansson et al., 2005; Olkkonen and Li, 2013;
265 Zhao and Ridgway, 2017). Hence, we asked whether the cholesterol sensing domain of ORP1L
266 is responsible for regulating dynein clustering on endolysosomal membranes. To address this
267 question, we first imaged ORP1L's spatial distribution on endolysosomes in wild type or ORP1L-
268 KO HeLa cells that express ORP1L WT-mCherry (Zhao and Ridgway, 2017) under low or high
269 cholesterol treatment conditions using super-resolution microscopy (Figure 3A). We again
270 analyzed isolated, round ORP1L WT-mCherry positive endolysosomes within a size range of 50-
271 700 nm in the super-resolution images. ORP1L appeared uniformly distributed (i.e. a single, large
272 ORP1L cluster covering the entire endolysosomal membrane) under low cholesterol conditions
273 and more clustered (i.e. multiple, smaller clusters covering only part of the endolysosomal
274 membrane) under high cholesterol conditions (Figure 3A).

275 To quantify the level of ORP1L clustering, we once again used Voronoi tessellation to segment
276 individual ORP1L clusters on endolysosomal membranes. This approach revealed an increased
277 number of ORP1L clusters with smaller area under high cholesterol (Figure S3A, mean clusters
278 per endolysosome = 2.6 ± 0.32 with a mean area of $23 \times 10^3 \text{ nm}^2$) compared to low cholesterol
279 (mean clusters per endolysosome = 1 ± 0.04 with a mean area of $10 \times 10^4 \text{ nm}^2$) conditions.
280 However, we also found that, surprisingly, the localization density of ORP1L was higher on
281 endolysosomes under low cholesterol compared to high cholesterol conditions (Figure S3B, mean
282 localizations per area = 0.017 ± 0.0006 for low and 0.007 ± 0.0003 for high cholesterol), suggesting
283 that more ORP1L binds to endolysosomes when their membrane cholesterol levels are lower.
284 The localization density of ORP1L under high or low cholesterol was consistent between three
285 independent biological replicates and the high cholesterol treatment consistently had lower
286 localization density compared to the low cholesterol treatment, suggesting that ORP1L expression
287 levels were consistent among experimental conditions (Figure S3C). When endogenous ORP1L
288 clustering level was quantified on CD63 positive endolysosomal compartments in wild type HeLa
289 cells using an ORP1L antibody, it also was more clustered under high cholesterol (mean clusters
290 per endolysosome = 4 ± 0.31 and 2 ± 0.02 , with a mean area of $14 \times 10^3 \text{ nm}^2$ and $45 \times 10^3 \text{ nm}^2$ under

291 high and low cholesterol, respectively) and had lower localization density (mean localizations per
292 area = 0.005 ± 0.0002 and 0.008 ± 0.0003 under high and low cholesterol, respectively) under high
293 cholesterol compared to low cholesterol conditions (Figure S3D-E), further demonstrating that the
294 results are not an artifact of ORP1L over-expression.

295 To ensure that the increased protein density with low cholesterol treatment does not confound
296 the clustering analysis using Voronoi tessellation, which is dependent on localization density, we
297 developed an alternative quantification method that is insensitive to differences in localization
298 density and protein amount (see Methods). To this end, we carried out Voronoi tessellation and
299 re-scaled the distribution of Voronoi polygon areas so that the mean area was set to unity such
300 that we could measure the clustering tendency of ORP1L without explicitly compensating for
301 different localization densities. For a clustered distribution, we expected to see a shift in the mode
302 of the reduced Voronoi polygon area distribution towards a smaller value. Indeed, the mode of
303 the distribution for endolysosomal compartments under high cholesterol conditions was shifted to
304 smaller polygon areas compared to low cholesterol conditions or compared to a simulated random
305 distribution, indicating that ORP1L is more clustered on endolysosomes with high membrane
306 cholesterol levels (Figure 3B). We further used a statistical test (Kullback-Leibler Divergence or
307 KL Divergence, see Methods) to determine a clustering tendency score that shows how much
308 ORP1L organization differed from a random distribution. The clustering tendency score was 0.75
309 under high cholesterol and 0.14 under low cholesterol (a 5-fold difference). These results further
310 confirm that ORP1L's organization on endolysosomal membranes deviated significantly more
311 from a random distribution under high cholesterol compared to low cholesterol conditions. Overall,
312 these super-resolution data show that ORP1L, like dynein, forms a similar number of nano-
313 clusters on endolysosomes having higher membrane cholesterol levels.

314 To determine if the differences in ORP1L's spatial distribution on endolysosomes were due to its
315 cholesterol binding, we expressed mCherry fused to a sterol binding deficient ORP1L mutant
316 lacking the residues 560–563 (ORP1L SBD-mCherry) (Vihervaara et al., 2011; Zhao and
317 Ridgway, 2017) in HeLa ORP1L KO cells (Figure 3C-D and Figure S3F-G). Super-resolution
318 images of the ORP1L SBD-mCherry mutant (Figure 3C) and both Voronoi cluster segmentation
319 analysis (Figure S3F, mean clusters per endolysosome = 1 ± 0.03 for high and 1.1 ± 0.04 for low
320 cholesterol conditions) and reduced Voronoi polygon area distribution analysis (Figure 3D,
321 Clustering tendency score for ORP1L-SBD: 0.1 for high and 0.09 for low cholesterol conditions)
322 showed that the distribution of the ORP1L-SBD mutant was uniform on endolysosomal
323 membranes independent of cholesterol levels. The membrane localization density of this mutant

324 was overall high under both high and low cholesterol conditions (Figure S3G, mean localizations
325 per area = 0.034 ± 0.0017 and 0.026 ± 0.00075 for high and low cholesterol, respectively) and at a
326 similar level to the full length ORP1L under low cholesterol conditions (Figure S3B, mean
327 localizations per area = 0.017 ± 0.00062). These results suggest that under low cholesterol or when
328 ORP1L lacks its cholesterol sensing domain, it is recruited to and binds phospholipids on
329 endolysosomes at a high level and likely in a non-specific manner.

330 Overall, these results strongly support that the cholesterol sensing domain of ORP1L regulates
331 its spatial distribution on endolysosomal membranes in a cholesterol dependent manner, with
332 high cholesterol leading to more specific ORP1L recruitment (Figure S3B) and formation of
333 ORP1L nano-clusters (Figure 3A-B).

334

335 **The cholesterol sensing domain of ORP1L regulates dynein clustering and endolysosomal**
336 **positioning in a cholesterol dependent manner.**

337 Having established that ORP1L's cholesterol sensing domain regulates ORP1L's level of
338 clustering on endolysosomal membranes in a cholesterol dependent manner, we next asked if
339 ORP1L's cholesterol sensing domain also impacts dynein clustering. We thus imaged dynein
340 using super-resolution microscopy in ORP1L-KO HeLa cells expressing the ORP1L SBD-
341 mCherry mutant. Analysis of dynein nano-clusters on endolysosomes under high and low
342 cholesterol conditions showed that dynein clustering was no longer sensitive to cholesterol levels
343 in cells expressing the ORP1L SBD-mCherry mutant as the sole ORP1L isoform (Figure 4A-B,
344 mean localizations per cluster = 51 ± 1.2 for high and 53 ± 0.88 for low cholesterol). In addition, the
345 level of dynein clustering in cells expressing the ORP1L SBD-mCherry mutant was similar to the
346 level of dynein clustering under low cholesterol conditions in cells expressing the full length
347 ORP1L WT-mCherry (mean localizations per cluster = 50 ± 1.9) (compare Figure 2B and Figure
348 4B).

349 While in cells expressing the ORP1L WT-mCherry, peripheral endolysosomes had more clustered
350 ORP1L (mean clusters per endolysosome = 1.4 ± 0.7) compared to peri-nuclear endolysosomes
351 (mean clusters per endolysosome = 1 ± 0.2), these differences disappeared in cells expressing the
352 ORP1L SBD-mCherry mutant (mean clusters per endolysosome = 1.1 ± 0.4 and 1.1 ± 0.6 for
353 peripheral and peri-nuclear, respectively) (FigureS4A-B). The sub-cellular positioning of
354 endolysosomes also became insensitive to cholesterol treatment in cells expressing the ORP1L
355 SBD-mCherry mutant and the endolysosomes were overall more scattered throughout the cell

356 under high or low cholesterol conditions as well as under physiological conditions (Figure S4C).
357 Finally, peripheral and peri-nuclear endolysosomes had similar level of dynein clustering in
358 untreated cells expressing the ORP1L SBD-mCherry mutant (Figure 4C, mean number of
359 localizations = 71 ± 6 for high and 66 ± 2 for low cholesterol). Taken together, these results suggest
360 that the higher copy number of dynein within nano-clusters on peripherally located
361 endolysosomes with higher cholesterol content is dependent on the cholesterol binding domain
362 of ORP1L (Figure 4D).

363

364 **Discussion**

365 Here using super resolution microscopy and quantitative analysis, we visualize the spatial
366 organization of dynein motor and its adapter protein ORP1L on endolysosomal membranes. We
367 find that dynein forms nano-clusters consisting of mainly single but also a small but significant
368 proportion of multiple copies of dynein motor. We note that the proportion of dynein multimers are
369 likely underestimated in our quantitative analysis due to steric effects impacting labeling
370 efficiency. Using perturbation experiments in which we manipulated endolysosomal membrane
371 cholesterol levels we show that the copy number of dynein within nano-clusters on endolysosomal
372 membrane is increased under high cholesterol. This increased clustering is regulated by the
373 cholesterol binding ability of ORP1L that forms part of the Rab7-ORP1L-RILP tripartite complex,
374 which recruits dynein to endolysosomal membranes.

375 Cryo-EM experiments demonstrated that BICD2 and Hook3 bind two copies of dynein motors
376 (Urnavicius et al., 2018) but whether the endolysosomal adapter proteins Rab7-ORP1L-RILP also
377 recruit multiple dyneins is unknown. Our results demonstrate that besides the stoichiometry
378 between motor proteins and their adapter proteins, additional mechanisms inside cells are likely
379 at play to increase motor protein clustering. We show that cholesterol levels and the ability of the
380 adapter protein ORP1L to sense and bind cholesterol impact the copy number of dynein motor
381 within nano-clusters on endolysosomal membranes. High cholesterol treatment increased the
382 proportion of nano-clusters containing dynein multimers. Peripheral endolysosomes also had a
383 higher proportion of nano-clusters with 2 copies of dynein compared to perinuclear
384 endolysosomes. The number of dynein nano-clusters per endolysosome, on the other hand, was
385 independent of cholesterol or endolysosome position. These results suggest that under high
386 cholesterol, more dynein is recruited into the dynein nano-clusters. An interesting hypothesis that

387 future experiments can test is that there are pre-existing hot spots, potentially cholesterol enriched
388 domains containing ORP1L, which may act as recruitment sites for multiple copies of dynein.

389 Endolysosome run length and velocity were also higher in the retrograde direction under high
390 cholesterol whereas anterograde run length and velocity was cholesterol independent. These
391 results suggest that having dynein present in multiple copies may be important for efficient
392 retrograde transport, which is consistent with the recent Cryo-EM and in vitro single molecule
393 imaging data showing that coupled dyneins move more processively and faster than single dynein
394 (Urnavicius et al., 2018).

395 Interestingly, ORP1L was present in higher amounts on endolysosomes under low cholesterol
396 compared to high cholesterol and its spatial distribution was uniform rather than clustered under
397 low cholesterol. However, increased amounts of ORP1L did not lead to more dynein recruitment,
398 to the contrary, the number of dynein motors within nano-clusters as well as the total number of
399 dynein motors on endolysosomes were decreased under low cholesterol. This result may be due
400 to the fact that ORP1L needs to be in a tripartite complex with Rab7 and RILP to recruit dynein
401 and such complex formation maybe compromised under low cholesterol conditions in which
402 ORP1L may bind the endolysosome membrane in a more non-specific manner. Future
403 experiments probing the spatial co-relationship between ORP1L, Rab7, RILP and dynein can
404 address this possibility.

405 Previous *in vitro* work showed that early phagosomes engulfing 2-micron sized polystyrene beads
406 isolated from dictyostelium cells were completely uniformly covered with dynein on their
407 membrane whereas late phagosomes that move unidirectionally towards the retrograde direction
408 had a highly clustered dynein distribution (Rai et al., 2016). These changes in dynein distribution
409 were correlated to the membrane cholesterol content of phagosomes. In contrast, our results
410 show that instead of uniformly covering the entire membrane, only a small number of dyneins are
411 associated to endolysosomal membranes *in vivo*. A dramatic shift from a uniform dynein coverage
412 to a highly clustered dynein distribution hence is likely not needed for regulating retrograde
413 transport of native cellular compartments as these previous experiments with non-native
414 compartments suggested. Instead, a small shift from mainly single copies of dynein to a small
415 proportion of dynein multimers is likely sufficient to bias retrograde transport of native sub-cellular
416 compartments. Our results are more in line with high speed dark field microscopy and optical
417 trapping experiments on axonal endosomes, which also suggested that up to 8 dynein motors
418 can dynamically cluster under load (Chowdary et al., 2018).

419 Interestingly, the number of dyneins within nano-clusters is higher for peripherally located
420 endolysosomes, which also have higher cholesterol levels. These results may seem
421 counterintuitive as dynein is responsible for retrograde transport and hence one may expect more
422 dynein clustering on endolysosomes accumulating in the peri-nuclear region. However, once
423 endolysosomes reach the peri-nuclear region, they may no longer require clustered dynein
424 multimers to maintain their peri-nuclear positioning. Dynein may dissociate from the membrane
425 to be recycled once endolysosomes are positioned in the peri-nuclear region. On the other hand,
426 peripherally located endolysosomes may depend on clustered dynein multimers to be transported
427 to and deposited at the peri-nuclear region. In addition, it is known that endolysosomes contact
428 the endoplasmic reticulum as they are trafficked within the cell cytoplasm (Friedman et al., 2013;
429 Rocha et al., 2009; Zhao and Ridgway, 2017). Such contacts lead to exchange of membrane
430 lipids and maturation of endolysosomes (van der Kant et al., 2013; Zhao and Ridgway, 2017). It
431 is plausible that multiple endolysosome-ER contacts during retrograde transport play a role in
432 lowering the cholesterol content of endolysosomes, potentially providing a mechanism for
433 dissociation of dynein and decreased dynein clustering once the endolysosomes reach their peri-
434 nuclear destination. Future correlative live-cell and super-resolution imaging experiments (Balint
435 et al., 2013; Mohan et al., 2019; Verdeny-Vilanova et al., 2017) will enable directly linking the
436 transport properties of endolysosomes to the level of dynein clustering on their membrane.

437 Previous studies showed that ORP1L, depending on its conformation, can either bind dynein or
438 make contacts with the ER-membrane (Oikkonen and Li, 2013; Rocha et al., 2009; Wijdeven et
439 al., 2016; Zhao and Ridgway, 2017). A change in ORP1L's conformation leads to shedding of
440 dynein and initiation of contact between ORP1L and the ER-membrane protein VAP to regulate
441 endolysosomal positioning (Rocha et al., 2009). Our results are consistent with these former
442 studies as we show that in addition to the level of dynein clustering, the recruitment of dynein to
443 endolysosomal compartments is also dependent on cholesterol levels. Here, we additionally show
444 that ORP1L forms nano-clusters on endolysosome membranes when the membrane cholesterol
445 level is high. In addition, not only more dynein is recruited to the endolysosomal membrane under
446 these conditions but also the proportion of dynein present as multimers within nano-clusters is
447 increased. Hence, multiple mechanisms, including recruitment of more dynein motors and
448 clustering of the recruited dynein motors on the endolysosomal membrane, may be at play to
449 increase the efficiency of retrograde transport and regulate endolysosomal positioning. It will be
450 interesting in the future to examine the differential impact of having more dynein that is not present
451 as multimers within nano-clusters versus having similar amount of dynein clustered in multimers
452 within nano-clusters on the transport and positioning of endolysosomes. It is plausible to

453 hypothesize that increased dynein recruitment in the absence of dynein clustering is not sufficient
454 for enhancing retrograde transport.

455 Overall, we propose an *in vivo* model dependent on cholesterol levels by which multiple dyneins
456 can be recruited and clustered on endolysosomal membranes leading to their efficient retrograde
457 transport and positioning (Fig. 4D). Increased dynein clustering in response to cholesterol levels
458 is likely to be functionally significant as it impacts the sub-cellular positioning of endolysosomal
459 compartments. Metabolic disorders that lead to accumulation of lipids including cholesterol in
460 endolysosomal compartments like Niemann Pick Disease (NPC) are typically associated with
461 alterations in endolysosomal homeostasis and function (Torres et al., 2017). In the future it would
462 be interesting to explore if the nanoscale organization of ORP1L and dynein is altered on
463 endolysosomal membranes in NPC and other lysosomal storage disorders leading to their
464 mislocalization within the cell and whether restoring the proper nanoscale organization of these
465 cytoskeletal proteins can restore endolysosomal function. It would also be interesting to determine
466 if similar mechanisms play a role in regulating kinesin clustering or in regulating transport of other
467 organelles including Golgi vesicles and autophagosomes. It would further be exciting to determine
468 the precise stoichiometry of adapter-motor complexes on organelle membranes to determine how
469 the stoichiometry can be precisely tuned to regulate organelle transport and positioning. Our work
470 establishes the methodology needed and opens the door to carry out these future studies.

471

472 **Materials and Methods**

473 **Cells and transfections**

474 Wild type HeLa cells were obtained from the American Type Culture Collection (CCL-2, ATCC,
475 Manassas, VA). HeLa-ORP1L-null cell lines, as well as mCherry-tagged ORP1L and ORP1L-
476 SBD constructs were a kind gift from Prof. Neale Ridgway (Dalhousie University, Depts. of
477 Pediatrics, and Biochemistry and Molecular Biology, Atlantic Research Centre, Halifax, Nova
478 Scotia, Canada). HeLa cells were grown in DMEM (GIBCO Laboratories, Grand Island, NY)
479 supplemented with 10% fetal bovine serum and antibiotics, and maintained in 5% CO₂ at
480 37°C. Cells were transiently transfected with mCherry-tagged wild type or mutant ORP1L at 70%
481 confluency using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's
482 protocol. Cells were subjected to experimental treatments 24 h after transfection.

483 **Pharmacological treatment of cells**

484 Lovastatin (Sigma 1370600) was converted from its inactive prodrug form to its active open acid
485 form by dissolving Lovastatin (52gms) in ethanol (95%, 1.04 ml), followed by addition of 1N NaOH
486 (813 μ l), followed by heating for 2 hrs at 50°C and neutralized with 1N HCL (pH 7.2). The volume
487 was made up to 13 ml by adding distilled water, giving 10mM active Lovastatin solution later
488 aliquoted and stored at -20°C(Keyomarsi, 1996). Mevalonic acid lactone (Sigma M4667, 1 gm)
489 was converted to its active form by dissolving in ethanol (3.5 ml), followed by addition of 1N NaOH
490 (4.2 ml) and heating for 2 hrs at 55°C. The solution was made up to 15.4 ml with distilled water
491 and neutralized with 1N HCL (pH 7.2), giving 500 mM of stock solution, later aliquoted and stored
492 at -20. U18666A (Sigma U3633) was dissolved in ethanol giving final concentration of
493 10mg/ml(Rocha et al., 2009). For cholesterol depletion treatment, cells were cultured in DMEM,
494 10% Lipoprotein deficient serum (Sigma S5394), 50uM Lovastatin, 230uM Mevalonate for 6 hrs
495 before fixing for immunostaining. For high cholesterol treatment cells were cultured in DMEM,
496 10% FBS and 3 μ g/ml U18666A for 12 hrs before fixing.

497 **Immunostating**

498 Hela ORP1L KO cells were transiently transfected with ORP1L WT-mCherry or ORP1L SBD-
499 mCherry, treated with U18666A/Lovastatin or not treated and immunostained for ORP1L and
500 dynein. Endogenous ORP1L was immunostained in untransfected Hela cells treated with
501 U18666A/Lovastatin or not treated. For ORP1LWT/SBD-mCherry and endogenous ORP1L
502 immunostaining, cells were fixed with 4% (Vol/Vol) Paraformaldehyde in PBS for 20 mins and for
503 dynein immunostaining, cells were fixed in prechilled 1:1 Ethanol/Methanol solution for 3 mins on
504 ice. The cells were blocked in blocking buffer (3% BSA, 0.2% Triton X-100 in PBS) for 1 hr. Cells
505 were incubated with primary antibodies: Chicken anti-mCherry (Novus biotech nbp2-2515, 1:500)
506 ,mouse anti-dynein (Abcam ab23905, 1:50 or 1:5000 for single dynein imaging) and rabbit anti-
507 ORP1L (Abcam ab131165, 1:100) in blocking buffer for 1 hr on a rocker. Cells were washed with
508 washing buffer (0.2% blocking buffer, .05% Triton X-100 in PBS) three times. Custom made
509 secondary antibodies were labeled with an Alexa Fluor 405–Alexa Fluor A647 activator/reporter
510 dye pair combination at concentrations (0.1-0.15 mg/ μ l) and used in the ratio of 1:50 in blocking
511 buffer for 40 mins, at RT on a rocker. Sample was then washed three times in PBS.

512 **Filipin staining**

513 Filipin (Sigma F4767) was lyophilized, aliquoted (250 μ g per aliquot) and stored at -80°C. Filipin
514 was resuspended in 5 μ l DMSO. Cells were fixed in 4% Paraformaldehyde for 20 mins and then
515 rinsed 3 times with PBS. Background autofluorescence was quenched with 50mM NH₄CL for 10

516 mins. Cells were incubated for 2 hrs with 100 µg/ ml working solution of Filipin in 3% BSA. Cells
517 were washed with 1% BSA in PBS three times before imaging. Imaging was performed
518 immediately.

519 **Western blot**

520 Western blot analysis was performed using the two-color Odyssey LI-COR (Lincoln, NE)
521 technique according to the manufacturer's protocol. A rabbit monoclonal antibody to ORP1L
522 (ab131165, Abcam), mouse monoclonal antibody to dynein (ab23905, Abcam), and a mouse
523 monoclonal antibody to detect GAPDH (clone 3B1E9, GenScript A01622–40) were used at a
524 dilution of 1:1,000 in blocking buffer. The secondary antibody IRDye800CW Donkey anti-Rabbit
525 and IRDye680RD Donkey anti-Mouse (LI-COR) were used in 1:10000 dilution for imaging in the
526 green 800-nm and red 700-nm channels, respectively.

527 **STORM Imaging**

528 Single-molecule imaging was done using imaging buffer comprising of 50 mM Tris, pH 7.5, 10
529 mM NaCl, 0.5 mg/mL glucose oxidase (Sigma, G2133), 40 µg/mL catalase (Roche Applied
530 Science, 106810), 10% (w/v) glucose and 10% (v/v) Ciseamine (77mg/ml of 360mM HCL) (Bates
531 et al., 2007). Images were acquired on the Oxford Nanoimager-S microscope which has the
532 following configuration: 405, 488, 561, and 640 nm lasers, 498–551 and 576–620 nm band-pass
533 filters in channel 1, and 665–705 nm band-pass filters in channel 2, 100× 1.4 NA objective
534 (Olympus), and a Hamamatsu Flash 4 V3 sCMOS camera. Localizations were acquired with 10-
535 ms exposure over 50,000 frames with 405 nm activation and 647 nm excitation. Images were
536 processed and localizations were obtained using the NimOS localization software (Oxford
537 Nanoimaging).

538 **Live cell imaging**

539 HeLa ORP1L KO cells were transfected with ORP1L WT-mCherry and treated with
540 U18666A/Lovastatin for 6 hrs, as most endolysosomes were peri-nuclear after 12 hrs of treatment
541 with U18666A. Videos were acquired on the Oxford Nanoimager-S microscope with 100 ms
542 exposure over 300 frames, 561 nm excitation with HiLo illumination and 37°C sample
543 temperature.

544 **Data Analysis**

545 STORM data Analysis: To identify dynein clusters on ORP1L positive compartments, the intensity
546 profile of conventional ORP1L image was used as a mask. Line intensity profile of the ORP1L

547 conventional image along x and y axis was plotted on image J, and the width across one third of
548 the full intensity maxima was considered as the mask (Figure S1B).

549 For quantitative analysis we used custom written MATLAB codes. A previously described method
550 was adapted that segments super-resolution images based on Voronoi tessellation of the
551 fluorophore localizations (Andronov et al., 2016; Levet et al., 2015). Voronoi tessellation of a
552 STORM image assigns a Voronoi polygon to each localization, such that the polygon area is
553 inversely proportional to the local localization density. The spatial distribution of dynein or ORP1L
554 localizations from each ORP1L positive endolysosome is represented by a set of Voronoi
555 polygons such that smaller polygon areas correspond to regions of higher density. The Voronoi
556 polygons at the endolysosomal edge are extremely large and were omitted for any quantification.
557 Dynein and ORP1L clusters were segmented by grouping adjacent Voronoi polygons with areas
558 less than a selected threshold and imposing a minimum number of localizations. For ORP1L WT-
559 mCherry, ORP1L SBD-mCherry, dynein (ORP1L positive endolysosomes) and dynein (ORP1L-
560 SBD positive endolysosomes), the selected area thresholds were 0.0156 px^2 , 0.02 px^2 , 0.01 px^2
561 and 0.01 px^2 , respectively and the minimum number of localizations imposed were 16, 10, 7 and
562 7, respectively. ORP1L localization density was calculated by normalizing the total number of
563 localizations per endolysosome by endolysosome area. Each endolysosome area was calculated
564 by summing up all of its Voronoi polygon areas. The low cholesterol treatment yielded
565 endolysosomes with ORP1L localization densities 4.5 times higher as compared to the high
566 cholesterol treated endolysosome localization densities. To compare endolysosomal ORP1L
567 distribution following cholesterol treatments, the ORP1L localization densities should be
568 comparable. To address this we divided the Voronoi polygon areas of each endolysosome by its
569 mean Voronoi polygon area, such that the mean localization density of each endolysosome is in
570 reduced units of 1. All reduced Voronoi polygon areas from each endolysosome for each treatment
571 were pulled together, and the histogram was plotted. The distribution of Voronoi areas from
572 uniformly simulated random points is fit to an analytical distribution (Tanemura, 2003). A method
573 for calculating the KL divergence between two histograms or between a histogram and an
574 analytical distribution (Perez-Cruz, 2008) was implemented in Matlab. The KL divergence scores
575 between the experimental reduced voronoi areas and the theoretical random distribution were
576 calculated to determine the clustering tendency score of each cholesterol treatment. ORP1L
577 reduced Voronoi Area analysis and number of clusters per endolysosome analysis were done
578 with endolysosomes with radius $< 350 \text{ nm}$. Dynein number of cluster per endolysosome analysis
579 has been done with endolysosomes with radius $< 350 \text{ nm}$ and dynein localizations per cluster
580 analysis has been done with endolysosomes with radius $< 400 \text{ nm}$.

581 Dynein copy number quantification: For single dynein IC74 calibration analysis (100 fold diluted
582 dynein antibody), dynein localizations were taken from the whole cell except the nucleus region
583 to avoid biased results and Voronoi analysis with subsequent cluster analysis was performed. For
584 quantification of dynein copy numbers, the single dynein data (localizations per cluster) was fit to
585 a lognormal distribution function to obtain the μ and σ values for the calibration function (f_1). Using
586 these values, the peripheral, perinuclear and high, low cholesterol dynein data (localizations per
587 cluster) were fit with functions ($f_1, f_2, f_3...$) with $f_2, f_3...$ corresponding to linear convolutions of f_1
588 with itself and having weights of $w_1, w_2, w_3...$. Residuals were calculated after each fit (f_1 alone
589 corresponding to N=1, or f_1 and f_2 corresponding to N=2, f_1, f_2 and f_3 corresponding to N=3 etc...).
590 The fitting was stopped at N=3 with the criterion that the residuals did not vary after N=3.

591 Fillipin Intensity: Filipin intensity was calculated using Image J 'plot profile' tool. All ORP1L positive
592 endolysosomes were analyzed by drawing a line segment across it and looking at its intensity
593 profile using the 'plot profile' tool. The average of 3-4 highest intensity points were taken and the
594 average background intensity was subtracted from that.

595 Live cell tracking: ORP1L WT-mCherry positive endolysosomes moving towards nucleus was
596 considered retrograde transport and the ones moving towards cell peripheral and away from the
597 nucleus was considered anterograde transport. Endolysosomal positions were tracked by a
598 semiautomated, custom-written, particle-tracking software. ORP1L mCherry positive Trajectories
599 were analyzed by performing a 2D Gaussian fit to the point spread function and
600 the x and y positions were determined.

601 A previously written custom MATLAB program was used to determine the active and passive
602 phases of the endolysosomal trajectory, as previously described (Verdeny-Vilanova et al., 2017).
603 As previously described and validated (Verdeny-Vilanova et al., 2017), a moving window analysis
604 (four-point segments) was performed along the trajectory data points and the ratio between the
605 total displacement (the initial and final points of the segment) and the sum of displacements
606 between the points within the segment was calculated. This ratio provides an estimate of the
607 linearity of the segment, and values close to 1 were considered active phases. A threshold ratio
608 of 0.6 was considered to distinguish between active and passive phases. Additional criteria like
609 calculating power-law exponent from the mean square displacement (MSD) and angle criterion
610 (successive displacement vectors showing angles less than 90° were categorized as passive)
611 were imposed to confirm the active or passive categorization. For segments categorized as
612 passive but containing fewer than 3 data points (300 ms) were considered to be inconclusive and
613 were merged with the segment before and after them. As previously described (Verdeny-Vilanova

614 et al., 2017), very short segments (with a total displacement <350 nm) that were categorized as
615 active were not considered for run length or velocity analysis. This cut-off displacement of 350
616 nm was chosen as endolysosomes move at an average speed of ~1-1.7 $\mu\text{m/s}$ and, in 3 frames
617 (300 ms), the expected displacement is ~300-510 nm. The run length and average speed were
618 obtained from the remaining trajectory segments categorized as active.

619

620 **Acknowledgements**

621 We thank Prof. Neale D. Ridgway, Dalhousie University for the HeLa cells that are a knockout for
622 ORP1L and for the ORP1L WT-mCherry and ORP1L SBD-mCherry constructs. We thank Prof.
623 Michael S. Marks, UPenn, for critical reading and feedback on the manuscript. ML acknowledges
624 funding from the National Institutes of Health/National Institutes for General Medical Sciences
625 (NIH/NIGMS) under the grant numbers: RO1 GM 133842-01 and 1RM1GM136511-01 and the
626 Center for Engineering and Mechanobiology (CEMB) an NSF Science and Technology Center
627 Pilot Award under grant agreement CMMI: 15-48571.

628

629 **Author Contributions**

630 ML and ST conceived of the study. ST prepared samples, carried out experiments, wrote software
631 and analyzed data. P.K.R. wrote software and implemented the renormalized voronoi area
632 distribution and KL-Divergence analysis methodology. E.M.S. maintained cell lines, carried out
633 western blot experiments, carried out all transfections, provided reagents and helped with sample
634 preparation. M.T.G. helped carry out dilution and calibration experiments. ML wrote the
635 manuscript, acquired funding and supervised the work. All authors provided feedback on the
636 manuscript.

637

638 **Competing Interests:** Authors declare no competing interests.


639

640

641

642

643 **Figures**



644

645 **Figure 1:** Dynein forms larger nano-clusters containing a higher proportion of dynein multimers
646 on endolysosomes positioned at the cell periphery:


647 (A) Cropped wide-field image of cells expressing full length ORP1L fused to mCherry (ORP1L
648 WT-mCherry, yellow) overlaid with super-resolution image of dynein (blue). Cell edge and
649 nucleus are highlighted in yellow dashed lines. A zoom of the white rectangle is shown in
650 which ORP1L WT-mCherry positive endolysosomes are highlighted with white circles.

651 (B) An overlay of wide-field image of ORP1L WT-mCherry (yellow) and super-resolution
652 image of immunostained dynein (image is color coded according to localization density
653 with higher density corresponding to white and lower density corresponding to cyan) for
654 an endolysosome positioned at the cell periphery (PP) and peri-nuclear region (PN) in
655 HeLa ORP1L-KO cells

656 (C) Box plot showing the number of localizations per dynein nano-cluster for peripherally
657 positioned endolysosomes (PP) ($n=195$ endolysosomes from $n=6$ cells, $n=2$ experiments,
658 mean 67 ± 1.9), peri-nuclearly positioned endolysosomes (PN) ($n=210$ endolysosomes

659 from $n=6$ cells, $n=2$ experiments, mean 54 ± 1.8) in ORP1L WT-mCherry expressing HeLa
660 ORP1L-KO cells and for dynein that has been labeled with a 100-fold dilution of the
661 primary antibody for sparsely labeling single IC74 subunits in HeLa WT cells (Calib) ($n=6$
662 cells, $n=1$ experiments, see methods, mean 42 ± 0.2). The box corresponds to 25-75
663 percentile, the line corresponds to the median, the cross corresponds to the mean, and
664 the whiskers correspond to 10-90 percentile. Statistical significance was assessed using
665 a Kolmogorov-Smirnov-test with a p-value of. ***: 0.001, ****: <0.0001 .

666 (D) Box plot showing the intensity of filipin, which binds cholesterol, on peripherally positioned
667 endolysosomes (PP) ($n=44$ endolysosomes from $n=4$ cells, $n=2$ experiments, mean
668 454 ± 40) versus peri-nuclearly positioned endolysosomes (PN) ($n=41$ endolysosomes
669 from $n=5$ cells, $n=2$ experiments, mean 312 ± 19) in ORP1L WT-mCherry expressing HeLa
670 ORP1L-KO cells. The box corresponds to 25-75 percentile, the line corresponds to the
671 median, the cross corresponds to the mean and the whiskers correspond to 10-90
672 percentile. Statistical significance was assessed using a Kolmogorov-Smirnov-test with a
673 p-value of 0.02



674

675 **Figure 2:** Dynein forms larger nano-clusters containing a higher proportion of dynein multimers
 676 on endolysosomes that have high cholesterol content compared to those that have low cholesterol
 677 content:

678 (A) An overlay of cropped wide-field image of ORP1L WT-mCherry (yellow) and super-
 679 resolution image of immunostained dynein (image is color coded according to localization
 680 density with higher density corresponding to white and lower density corresponding to
 681 cyan) for an endolysosome treated with U18666A (High Chol) or Lovastatin (Low Chol) in
 682 HeLa ORP1L-KO cells.

683 (B) Box plot showing the number of localizations per dynein nano-cluster for endolysosomes
 684 in ORP1L WT-mCherry expressing HeLa ORP1L-KO cells treated with U18666A (High

685 Chol) ($n=224$ endolysosomes from $n=6$ cells, $n=2$ experiments, mean 71 ± 1.9) versus
686 Lovastatin (Low Chol) ($n=217$ endolysosomes from $n=6$ cells, $n=2$ experiments, mean
687 50 ± 1.9). The box corresponds to 25-75 percentile, the line corresponds to the median, the
688 cross corresponds to the mean and the whiskers correspond to 10-90 percentile.
689 Statistical significance was assessed using a Kolmogorov-Smirnov-test with a p -value
690 <0.0001 .

691 (C) Box plot showing the number of localizations per dynein nano-cluster for peripherally or
692 peri-nuclearly positioned endolysosomes in ORP1L WT-mCherry expressing Hela
693 ORP1L-KO cells treated with U18666A (High Chol PP: $n=70$ endolysosomes from $n=6$
694 cells, $n=2$ experiments, mean 79 ± 5 and High Chol PN: $n=154$ endolysosomes from $n=6$
695 cells, $n=2$ experiments, mean 70 ± 2) or Lovastatin (Low Chol PP; $n=110$ endolysosomes
696 from $n=6$ cells, $n=2$ experiments, mean 50 ± 2.7 and Low Chol PN; $n=107$ endolysosomes
697 from $n=6$ cells, $n=2$ experiments, mean 51 ± 2.8 , respectively). The box corresponds to 25-
698 75 percentile, the line corresponds to the median, the cross corresponds to the mean and
699 the whiskers correspond to 10-90 percentile. Statistical significance was assessed using
700 a Kolmogorov-Smirnov-test with a p -value of $n.s.: 0.27$, $n.s.: 0.93$, $** : 0.001$, $**** : <0.0001$.


701 (D) Box plot showing the number of localizations per dynein nano-cluster for peripherally
702 positioned endolysosomes in ORP1L WT-mCherry expressing Hela ORP1L-KO cells,
703 untreated (No Treat) ($n=195$ endolysosomes from $n=6$ cells, $n=2$ experiments, mean
704 67 ± 1.9) and treated with U18666A (High Chol) ($n=70$ endolysosomes from $n=6$ cells, $n=2$
705 experiments, mean 79 ± 5); as well as in peri-nuclearly positioned endolysosomes in
706 untreated cells (No Treat) ($n=210$ endolysosomes from $n=6$ cells, $n=2$ experiments, mean
707 54 ± 1.8) and Lovastatin treated cells (Low Chol) ($n=107$ endolysosomes from $n=6$ cells,
708 $n=2$ experiments, mean 51 ± 2.8). The box corresponds to 25-75 percentile, the line
709 corresponds to the median, the cross corresponds to the mean and the whiskers
710 correspond to 10-90 percentile. Statistical significance was assessed using a Kolmogorov-
711 Smirnov-test with a p -value of 0.1353 and 0.7 .

712 (E) Box plot showing the retrograde run length of endolysosomes in ORP1L WT-mCherry
713 expressing Hela ORP1L-KO cells treated with U18666A (High Chol) ($n=135$
714 endolysosomes from $n=40$ cells, $n=3$ experiments, mean 2.7 ± 2) or Lovastatin (Low Chol)
715 ($n=100$ endolysosomes from $n=40$ cells, $n=3$ experiments, mean 1.9 ± 1); as well as
716 retrograde velocity of endolysosomes in U18666A treated cells (High Chol) ($n=135$
717 endolysosomes from $n=40$ cells, $n=3$ experiments, mean 1.7 ± 0.9) or Lovastatin treated
718 cells (Low Chol) ($n=100$ endolysosomes from $n=40$ cells, $n=3$ experiments, mean 1 ± 0.7).

719 *The box corresponds to 25-75 percentile, the line corresponds to the median, the cross*
720 *corresponds to the mean and the whiskers correspond to 10-90 percentile. Statistical*
721 *significance was assessed using a Kolmogorov-Smirnov-test with a p-value of 0.01 and*
722 *<0.0001.*

723 *(F) Box plot showing the anterograde run length of endolysosomes in ORP1L WT-mCherry*
724 *expressing Hela ORP1L-KO cells treated with U18666A (High Chol) (n=135*
725 *endolysosomes from n=40 cells, n=3 experiments, mean 1.2 ± 0.8) or Lovastatin (Low*
726 *Chol) (n=130 endolysosomes from n=40 cells, n=3 experiments, mean 1.4 ± 0.9); as well*
727 *as anterograde velocity of endolysosomes in U18666A treated cells (High chol) (n=135*
728 *endolysosomes from n=40 cells, n=3 experiments, mean 0.9 ± 0.4) versus Lovastatin*
729 *treated cell (Low Chol) (n=130 endolysosomes from n=40 cells, n=3 experiments, mean*
730 *1 ± 0.6). The box corresponds to 25-75 percentile, the line corresponds to the median, the*
731 *cross corresponds to the mean and the whiskers correspond to 10-90 percentile.*
732 *Statistical significance was assessed using a Kolmogorov-Smirnov-test with a p-value of*
733 *0.01 and 0.17*

734



735

736 **Figure 3:** ORP1L is more clustered on endolysosomes having higher cholesterol levels in a
737 manner dependent on its cholesterol binding domain:

738 (A) Super-resolution images of full length ORP1L (ORP1L WT-mCherry) in HeLa ORP1L-KO
739 cells treated with U18666A (High Chol, upper panels) and Lovastatin (Low Chol, lower
740 panels).

741 (B) Log plot of the Reduced Voronoi Polygon area distribution for super-resolution images of
742 full length ORP1L (ORP1L WT-mCherry) in HeLa ORP1L-KO cells treated with U18666A
743 (dark green, High Chol) ($n=95$ endolysosomes from $n=6$ cells, $n=2$ experiments),
744 Lovastatin (light green, Low Chol) ($n=107$ endolysosomes from $n=6$ cells, $n=2$
745 experiments) and for a random distribution of localizations (yellow, Random). The dashed
746 lines are a guide to the eye to highlight the shift in the peak position of Reduced Voronoi
747 Polygon area distributions with cholesterol treatment for full length ORP1L (ORP1L WT-


748 *mCherry*) and sterol binding deficient *ORP1L* mutant lacking residues 560-563 (*ORP1L*
749 *SBD-mCherry*).

750 (C) Super-resolution images of sterol binding deficient *ORP1L* mutant lacking residues 560-
751 563 (*ORP1L SBD-mCherry*) in *Hela ORP1L-KO* cells treated with *U18666A* (High Chol,
752 upper panels) and *Lovastatin* (Low Chol, lower panels).

753 (D) Log plot of the Reduced Voronoi Polygon area distribution for super-resolution images of
754 sterol binding deficient *ORP1L* mutant lacking residues 560-563 (*mCherry-ORP1L-SBD*)
755 in *Hela ORP1L-KO* cells treated with *U18666A* (dark green, High Chol) ($n=120$
756 endolysosomes from $n=6$ cells, $n=2$ experiments), *Lovastatin* (light green, Low Chol)
757 ($n=170$ endolysosomes from $n=6$ cells, $n=2$ experiments) and for a random distribution of
758 localizations (yellow, Random).

759

760



761

762 **Figure 4:** Dynein nano-clusters are insensitive to cholesterol levels in cells expressing sterol
763 binding deficient *ORP1L* mutant:

764 (A) An overlay of cropped wide-field image of *ORP1L WT-mCherry* (yellow) and super-
765 resolution image of immunostained dynein (image is color coded according to localization
766 density with higher density corresponding to white and lower density corresponding to
767 cyan) in *Hela ORP1L-KO* cells expressing sterol binding deficient *ORP1L* mutant lacking

768 *residues 560-563 (ORP1L SBD-mCherry) treated with U18666A (High Chol) or Lovastatin*
769 *(Low Chol)*

770 *(B) Box plot showing the number of localizations per dynein nano-cluster for endolysosomes*
771 *in HeLa ORP1L-KO cells expressing the sterol binding deficient ORP1L mutant lacking*
772 *residues 560-563 (ORP1L SBD-mCherry) and treated with U18666A (High Chol) (n=450*
773 *endolysosomes from n=6 cells, n=2 experiments, mean 51 ± 1.2) or Lovastatin (Low Chol)*
774 *(n=300 endolysosomes from n=6 cells, n=2 experiments, mean 53 ± 0.88). The box*
775 *corresponds to 25-75 percentile, the line corresponds to the median, the cross*
776 *corresponds to the mean and the whiskers correspond to 10-90 percentile. Statistical*
777 *significance was assessed using a Kolmogorov-Smirnov-test with a p-value of 0.06.*

778 *(C) Box plot showing the number of localizations per dynein nano-cluster for peripherally*
779 *positioned endolysosomes (PP) (n=100 endolysosomes from n=5 cells, n=2 experiments,*
780 *mean 71 ± 6) and peri-nuclearly positioned endolysosomes (PN) (n=150 endolysosomes*
781 *from n=5 cells, n=2 experiments, mean 66 ± 2) in HeLa ORP1L-KO cells expressing the*
782 *sterol binding deficient ORP1L mutant lacking residues 560-563 (ORP1L SBD-mCherry).*
783 *The box corresponds to 25-75 percentile, the line corresponds to the median, the cross*
784 *corresponds to the mean and the whiskers correspond to 10-90 percentile. Statistical*
785 *significance was assessed using a Kolmogorov-Smirnov-test with a p-value of 0.44.*

786 *(D) Proposed model of how cholesterol levels and ORP1L regulate dynein nano-clustering*
787 *and endolysosome positioning: Peripheral lysosomes with higher cholesterol content have*
788 *a more clustered organization of ORP1L and dynein likely leading to efficient retrograde*
789 *transport (blue arrow). Perinuclear lysosomes having lower cholesterol content have more*
790 *uniform ORP1L organization leading to lower dynein recruitment and clustering likely*
791 *facilitating endolysosome anchoring at the peri-nuclear region or anterograde trafficking*
792 *back to the cell periphery.*

793

794 **References**

795 Abdul-Hammed, M., Breiden, B., Adebayo, M.A., Babalola, J.O., Schwarzmann, G., and Sandhoff, K. (2010).
796 Role of endosomal membrane lipids and NPC2 in cholesterol transfer and membrane fusion. *J Lipid Res*
797 *51*, 1747-1760.

798 Andronov, L., Orlov, I., Lutz, Y., Vonesch, J.L., and Klaholz, B.P. (2016). ClusterViSu, a method for clustering
799 of protein complexes by Voronoi tessellation in super-resolution microscopy. *Sci Rep* *6*, 24084.

- 800 Arumugam, S., and Kaur, A. (2017). The Lipids of the Early Endosomes: Making Multimodality Work.
801 *Chembiochem* *18*, 1053-1060.
- 802 Balint, S., Verdeny Vilanova, I., Sandoval Alvarez, A., and Lakadamyali, M. (2013). Correlative live-cell and
803 superresolution microscopy reveals cargo transport dynamics at microtubule intersections. *Proc Natl Acad*
804 *Sci U S A* *110*, 3375-3380.
- 805 Bates, M., Huang, B., Dempsey, G.T., and Zhuang, X. (2007). Multicolor super-resolution imaging with
806 photo-switchable fluorescent probes. *Science* *317*, 1749-1753.
- 807 Beatty, W.L. (2006). Trafficking from CD63-positive late endocytic multivesicular bodies is essential for
808 intracellular development of *Chlamydia trachomatis*. *J Cell Sci* *119*, 350-359.
- 809 Belyy, V., Schlager, M.A., Foster, H., Reimer, A.E., Carter, A.P., and Yildiz, A. (2016). The mammalian
810 dynein-dynactin complex is a strong opponent to kinesin in a tug-of-war competition. *Nat Cell Biol* *18*,
811 1018-1024.
- 812 Bissig, C., and Gruenberg, J. (2013). Lipid sorting and multivesicular endosome biogenesis. *Cold Spring*
813 *Harb Perspect Biol* *5*, a016816.
- 814 Brown, C.L., Maier, K.C., Stauber, T., Ginkel, L.M., Wordeman, L., Vernos, I., and Schroer, T.A. (2005).
815 Kinesin-2 is a motor for late endosomes and lysosomes. *Traffic* *6*, 1114-1124.
- 816 Brugger, B., Sandhoff, R., Wegehingel, S., Gorgas, K., Malsam, J., Helms, J.B., Lehmann, W.D., Nickel, W.,
817 and Wieland, F.T. (2000). Evidence for segregation of sphingomyelin and cholesterol during formation of
818 COPI-coated vesicles. *J Cell Biol* *151*, 507-518.
- 819 Cabukusta, B., and Neefjes, J. (2018). Mechanisms of lysosomal positioning and movement. *Traffic* *19*,
820 761-769.
- 821 Cardoso, C.M., Groth-Pedersen, L., Hoyer-Hansen, M., Kirkegaard, T., Corcelle, E., Andersen, J.S., Jaattela,
822 M., and Nylandsted, J. (2009). Depletion of kinesin 5B affects lysosomal distribution and stability and
823 induces peri-nuclear accumulation of autophagosomes in cancer cells. *PLoS One* *4*, e4424.
- 824 Cella Zanacchi, F., Manzo, C., Magrassi, R., Derr, N.D., and Lakadamyali, M. (2019). Quantifying Protein
825 Copy Number in Super Resolution Using an Imaging-Invariant Calibration. *Biophys J* *116*, 2195-2203.
- 826 Chowdary, P.D., Kaplan, L., Che, D.L., and Cui, B. (2018). Dynamic Clustering of Dyneins on Axonal
827 Endosomes: Evidence from High-Speed Darkfield Imaging. *Biophys J* *115*, 230-241.
- 828 Chowdhury, S., Ketcham, S.A., Schroer, T.A., and Lander, G.C. (2015). Structural organization of the
829 dynein-dynactin complex bound to microtubules. *Nat Struct Mol Biol* *22*, 345-347.
- 830 Ehmman, N., van de Linde, S., Alon, A., Ljaschenko, D., Keung, X.Z., Holm, T., Rings, A., DiAntonio, A.,
831 Hallermann, S., Ashery, U., *et al.* (2014). Quantitative super-resolution imaging of Bruchpilot distinguishes
832 active zone states. *Nature Communications* *5*, 4650.
- 833 Elshenawy, M.M., Canty, J.T., Oster, L., Ferro, L.S., Zhou, Z., Blanchard, S.C., and Yildiz, A. (2019). Cargo
834 adaptors regulate stepping and force generation of mammalian dynein-dynactin. *Nat Chem Biol* *15*, 1093-
835 1101.

- 836 Elshenawy, M.M., Kusakci, E., Volz, S., Baumbach, J., Bullock, S.L., and Yildiz, A. (2020). Lis1 activates
837 dynein motility by modulating its pairing with dynactin. *Nat Cell Biol* 22, 570-578.
- 838 Encalada, S.E., Szpankowski, L., Xia, C.H., and Goldstein, L.S. (2011). Stable kinesin and dynein assemblies
839 drive the axonal transport of mammalian prion protein vesicles. *Cell* 144, 551-565.
- 840 Ferro, L.S., Can, S., Turner, M.A., ElShenawy, M.M., and Yildiz, A. (2019). Kinesin and dynein use distinct
841 mechanisms to bypass obstacles. *Elife* 8.
- 842 Franke, C., Repnik, U., Segeletz, S., Brouilly, N., Kalaidzidis, Y., Verbavatz, J.M., and Zerial, M. (2019).
843 Correlative single-molecule localization microscopy and electron tomography reveals endosome
844 nanoscale domains. *Traffic* 20, 601-617.
- 845 Friedman, J.R., Dibenedetto, J.R., West, M., Rowland, A.A., and Voeltz, G.K. (2013). Endoplasmic
846 reticulum-endosome contact increases as endosomes traffic and mature. *Mol Biol Cell* 24, 1030-1040.
- 847 Fu, M.M., and Holzbaur, E.L. (2014). Integrated regulation of motor-driven organelle transport by
848 scaffolding proteins. *Trends Cell Biol* 24, 564-574.
- 849 Fu, M.M., Nirschl, J.J., and Holzbaur, E.L.F. (2014). LC3 binding to the scaffolding protein JIP1 regulates
850 processive dynein-driven transport of autophagosomes. *Dev Cell* 29, 577-590.
- 851 Gould, G.W., and Lippincott-Schwartz, J. (2009). New roles for endosomes: from vesicular carriers to multi-
852 purpose platforms. *Nat Rev Mol Cell Biol* 10, 287-292.
- 853 Granger, E., McNee, G., Allan, V., and Woodman, P. (2014). The role of the cytoskeleton and molecular
854 motors in endosomal dynamics. *Semin Cell Dev Biol* 31, 20-29.
- 855 Guardia, C.M., Farias, G.G., Jia, R., Pu, J., and Bonifacino, J.S. (2016). BORC Functions Upstream of Kinesins
856 1 and 3 to Coordinate Regional Movement of Lysosomes along Different Microtubule Tracks. *Cell Rep* 17,
857 1950-1961.
- 858 Hendricks, A.G., Perlson, E., Ross, J.L., Schroeder, H.W., 3rd, Tokito, M., and Holzbaur, E.L. (2010). Motor
859 coordination via a tug-of-war mechanism drives bidirectional vesicle transport. *Curr Biol* 20, 697-702.
- 860 Hu, Y.B., Dammer, E.B., Ren, R.J., and Wang, G. (2015). The endosomal-lysosomal system: from
861 acidification and cargo sorting to neurodegeneration. *Transl Neurodegener* 4, 18.
- 862 Huotari, J., and Helenius, A. (2011). Endosome maturation. *EMBO J* 30, 3481-3500.
- 863 Hyttinen, J.M., Niittykoski, M., Salminen, A., and Kaarniranta, K. (2013). Maturation of autophagosomes
864 and endosomes: a key role for Rab7. *Biochim Biophys Acta* 1833, 503-510.
- 865 Johansson, M., Lehto, M., Tanhuanpaa, K., Cover, T.L., and Olkkonen, V.M. (2005). The oxysterol-binding
866 protein homologue ORP1L interacts with Rab7 and alters functional properties of late endocytic
867 compartments. *Mol Biol Cell* 16, 5480-5492.
- 868 Johansson, M., Rocha, N., Zwart, W., Jordens, I., Janssen, L., Kuijl, C., Olkkonen, V.M., and Neefjes, J.
869 (2007). Activation of endosomal dynein motors by stepwise assembly of Rab7-RILP-p150Glued, ORP1L,
870 and the receptor betalll spectrin. *J Cell Biol* 176, 459-471.

- 871 Keyomarsi, K. (1996). Synchronization of mammalian cells by Lovastatin. *Methods in Cell Science* 18, 109-
872 114.
- 873 Kimura, S., Noda, T., and Yoshimori, T. (2008). Dynein-dependent movement of autophagosomes
874 mediates efficient encounters with lysosomes. *Cell Struct Funct* 33, 109-122.
- 875 Klumperman, J., and Raposo, G. (2014). The complex ultrastructure of the endolysosomal system. *Cold*
876 *Spring Harb Perspect Biol* 6, a016857.
- 877 Kobayashi, T., Beuchat, M.H., Chevallier, J., Makino, A., Mayran, N., Escola, J.M., Lebrand, C., Cosson, P.,
878 Kobayashi, T., and Gruenberg, J. (2002). Separation and characterization of late endosomal membrane
879 domains. *J Biol Chem* 277, 32157-32164.
- 880 Korolchuk, V.I., and Rubinsztein, D.C. (2011). Regulation of autophagy by lysosomal positioning.
881 *Autophagy* 7, 927-928.
- 882 Korolchuk, V.I., Saiki, S., Lichtenberg, M., Siddiqi, F.H., Roberts, E.A., Imarisio, S., Jahreiss, L., Sarkar, S.,
883 Futter, M., Menzies, F.M., *et al.* (2011). Lysosomal positioning coordinates cellular nutrient responses. *Nat*
884 *Cell Biol* 13, 453-460.
- 885 Lemmon, M.A. (2008). Membrane recognition by phospholipid-binding domains. *Nat Rev Mol Cell Biol* 9,
886 99-111.
- 887 Levet, F., Hosy, E., Kechkar, A., Butler, C., Beghin, A., Choquet, D., and Sibarita, J.B. (2015). SR-Tesseler: a
888 method to segment and quantify localization-based super-resolution microscopy data. *Nat Methods* 12,
889 1065-1071.
- 890 Maday, S., Twelvetrees, A.E., Moughamian, A.J., and Holzbaur, E.L. (2014). Axonal transport: cargo-specific
891 mechanisms of motility and regulation. *Neuron* 84, 292-309.
- 892 McKenney, R.J., Huynh, W., Tanenbaum, M.E., Bhabha, G., and Vale, R.D. (2014). Activation of cytoplasmic
893 dynein motility by dynactin-cargo adapter complexes. *Science* 345, 337-341.
- 894 Mohan, N., Sorokina, E.M., Verdeny, I.V., Alvarez, A.S., and Lakadamyali, M. (2019). Detyrosinated
895 microtubules spatially constrain lysosomes facilitating lysosome-autophagosome fusion. *J Cell Biol* 218,
896 632-643.
- 897 Nirschl, J.J., Magiera, M.M., Lazarus, J.E., Janke, C., and Holzbaur, E.L. (2016). alpha-Tubulin Tyrosination
898 and CLIP-170 Phosphorylation Regulate the Initiation of Dynein-Driven Transport in Neurons. *Cell Rep* 14,
899 2637-2652.
- 900 Olenick, M.A., and Holzbaur, E.L.F. (2019). Dynein activators and adaptors at a glance. *J Cell Sci* 132.
- 901 Olkkonen, V.M., and Li, S. (2013). Oxysterol-binding proteins: sterol and phosphoinositide sensors
902 coordinating transport, signaling and metabolism. *Prog Lipid Res* 52, 529-538.
- 903 Perez-Cruz, F. (2008). Kullback-Leibler divergence estimation of continuous distributions. Paper presented
904 at: IEEE international symposium on information theory.
- 905 Pfeffer, S.R. (2001). Rab GTPases: specifying and deciphering organelle identity and function. *Trends Cell*
906 *Biol* 11, 487-491.

- 907 Pu, J., Guardia, C.M., Keren-Kaplan, T., and Bonifacino, J.S. (2016). Mechanisms and functions of lysosome
908 positioning. *J Cell Sci* *129*, 4329-4339.
- 909 Puchner, E.M., Walter, J.M., Kasper, R., Huang, B., and Lim, W.A. (2013). Counting molecules in single
910 organelles with superresolution microscopy allows tracking of the endosome maturation trajectory. *Proc*
911 *Natl Acad Sci U S A* *110*, 16015-16020.
- 912 Rai, A., Pathak, D., Thakur, S., Singh, S., Dubey, A.K., and Mallik, R. (2016). Dynein Clusters into Lipid
913 Microdomains on Phagosomes to Drive Rapid Transport toward Lysosomes. *Cell* *164*, 722-734.
- 914 Reck-Peterson, S.L., Redwine, W.B., Vale, R.D., and Carter, A.P. (2018). The cytoplasmic dynein transport
915 machinery and its many cargoes. *Nat Rev Mol Cell Biol* *19*, 382-398.
- 916 Redpath, G.M.I., Betzler, V.M., Rossatti, P., and Rossy, J. (2020). Membrane Heterogeneity Controls
917 Cellular Endocytic Trafficking. *Front Cell Dev Biol* *8*, 757.
- 918 Rocha, N., Kuijl, C., van der Kant, R., Janssen, L., Houben, D., Janssen, H., Zwart, W., and Neefjes, J. (2009).
919 Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late
920 endosome positioning. *J Cell Biol* *185*, 1209-1225.
- 921 Rosa-Ferreira, C., and Munro, S. (2011). Arl8 and SKIP act together to link lysosomes to kinesin-1. *Dev Cell*
922 *21*, 1171-1178.
- 923 Schroeder, C.M., and Vale, R.D. (2016). Assembly and activation of dynein-dynactin by the cargo adaptor
924 protein Hook3. *J Cell Biol* *214*, 309-318.
- 925 Soppina, V., Rai, A.K., Ramaiya, A.J., Barak, P., and Mallik, R. (2009). Tug-of-war between dissimilar teams
926 of microtubule motors regulates transport and fission of endosomes. *Proc Natl Acad Sci U S A* *106*, 19381-
927 19386.
- 928 Tanemura, M. (2003). Statistical distributions of Poisson Voronoi cells in two and three dimensions.
929 *FORMA-TOKYO* *18*, 221-247.
- 930 Torres, S., Balboa, E., Zanlungo, S., Enrich, C., Garcia-Ruiz, C., and Fernandez-Checa, J.C. (2017). Lysosomal
931 and Mitochondrial Liaisons in Niemann-Pick Disease. *Front Physiol* *8*, 982.
- 932 Urnavicius, L., Lau, C.K., Elshenawy, M.M., Morales-Rios, E., Motz, C., Yildiz, A., and Carter, A.P. (2018).
933 Cryo-EM shows how dynactin recruits two dyneins for faster movement. *Nature* *554*, 202-206.
- 934 van der Kant, R., Zondervan, I., Janssen, L., and Neefjes, J. (2013). Cholesterol-binding molecules MLN64
935 and ORP1L mark distinct late endosomes with transporters ABCA3 and NPC1. *J Lipid Res* *54*, 2153-2165.
- 936 Vanlandingham, P.A., and Ceresa, B.P. (2009). Rab7 regulates late endocytic trafficking downstream of
937 multivesicular body biogenesis and cargo sequestration. *J Biol Chem* *284*, 12110-12124.
- 938 Verdeny-Vilanova, I., Wehnekamp, F., Mohan, N., Sandoval Alvarez, A., Borbely, J.S., Otterstrom, J.J.,
939 Lamb, D.C., and Lakadamyali, M. (2017). 3D motion of vesicles along microtubules helps them to
940 circumvent obstacles in cells. *J Cell Sci* *130*, 1904-1916.
- 941 Vihervaara, T., Uronen, R.L., Wohlfahrt, G., Bjorkhem, I., Ikonen, E., and Olkkonen, V.M. (2011). Sterol
942 binding by OSBP-related protein 1L regulates late endosome motility and function. *Cell Mol Life Sci* *68*,
943 537-551.

- 944 Wijdeven, R.H., Janssen, H., Nahidiazar, L., Janssen, L., Jalink, K., Berlin, I., and Neefjes, J. (2016).
945 Cholesterol and ORP1L-mediated ER contact sites control autophagosome transport and fusion with the
946 endocytic pathway. *Nat Commun* 7, 11808.
- 947 Znacchi, F.C., Manzo, C., Alvarez, A.S., Derr, N.D., Garcia-Parajo, M.F., and Lakadamyali, M. (2017). A DNA
948 origami platform for quantifying protein copy number in super-resolution. *Nat Methods* 14, 789-792.
- 949 Zhao, K., and Ridgway, N.D. (2017). Oxysterol-Binding Protein-Related Protein 1L Regulates Cholesterol
950 Egress from the Endo-Lysosomal System. *Cell Rep* 19, 1807-1818.
- 951